Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.58 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | FABP3 | P05413 | 1/20 | 0.56 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.51 |
| ▸ | SELP | P16109 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 2/20 | 0.47 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26221695 | 0.90 | LPAR3 (0.74) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL26221785 | 0.90 | LPAR3 (0.74) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL27068543 | 0.89 | LPAR3 (0.52) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| Tributyrin SCHEMBL14638860 | 0.89 | ALDH1A1 (0.60) | LPAR3LPAR1ENPP2SMN1; SMN2LPAR2 | |
| SCHEMBL27068460 | 0.88 | LPAR3 (0.51) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL27068568 | 0.88 | LPAR3 (0.51) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL27068529 | 0.87 | LPAR3 (0.56) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL26221681 | 0.87 | LPAR3 (0.70) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL27068513 | 0.87 | LPAR3 (0.50) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 | |
| SCHEMBL27068565 | 0.86 | LPAR3 (0.55) | LPAR3LPAR1ENPP2SMN1; SMN2FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975111-B2 | Cardiopathy-reducing phosphodiester lipids | SIGNPATH PHARMA, INC. (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975111-B2 | Cardiopathy-reducing phosphodiester lipids | TNNT2, TNNI3, FABP3 | LPAR3 219/4885LPAR1 229/4885ENPP2 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.